Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
María José SernaJose Miguel Rivera-CaravacaRocío Gonzalez-ConejeroMaría Asunción Esteve-PastorMariano ValdésVicente VicenteGregory Y H LipVanessa RoldánFrancisco MarínPublished in: European journal of clinical investigation (2018)
Adding pharmacogenetic factors (ie polymorphisms of the VKORC1 and CYP2C9 genes) to the HAS-BLED score does not improve the prediction or discrimination performance for major bleeding.